Applied Radiology - Development and Use of Elucirem (gadopiclenol) injection, a Macrocyclic, High-Relaxibity GBCA for CE-MRI

Clinical Applications & Imaging Considerations of Gadopiclenol Injection

Lawrence Tanenbaum, MD, FACR

Estimated time for completion: 1.0 hour • Date of Release: May 10, 2023 • Expiration Date: March 31, 2023

In September 2022, Gadopiclenol injection, which is both macrocyclic (stable) and has high relaxivity properties received FDA marketing approval and may provide dosing options that can decrease gadolinium exposure, particularly in vulnerable patients

In this accredited Expert Forum webinar, the assessment of Gadopiclenol injection in neuro, body, and pediatric MR imaging will be presented by a panel of MR imaging experts and will include commentary from Lawrence N. Tanenbaum, MD. To encourage audience participation, a live Q & A session will follow the discussion.

Learning Objectives

At the conclusion of this activity, participants should be able to:

Explain the properties that distinguish Gadopiclenol injection from the other high-relaxivity and conventional gadolinium-based contrast agents.
Describe the clinical use of Gadopiclenol injection in neuro, body, and pediatric MRI applications.
Describe the clinical development program of Gadopiclenol injection for neuro and body MRI applications.
Apply clinical considerations and dosing options when selecting a macrocyclic, high relaxivity, MRI contrast in vulnerable patient populations.

Accreditation

This course is approved by the The Association for Medical Imaging Management (AHRA) for 1.0 "Category A" ARRT and CRA continuing education credit.

Commercial Support

This program has been supported by Guerbet LLC.

To view the program and complete the Post-Exam and claim credits select Profession below.

(Site Registration/Login Required)

Development and Use of Elucirem (gadopiclenol) injection, a Macrocyclic, High-Relaxibity GBCA for CE-MRI

Lawrence Tanenbaum, MD, FACR; Laurie A. Loevner, MD; Donna Roberts, MD; Jeffrey Weinreb, MD; Ahmed Abdelal, PharmD

Estimated time for completion: 1.0 hour • Date of Release: February 24, 2023 • Expiration Date: March 31, 2026

After decades of administrations, substantial evidence has accumulated for the efficacy and safety of gadolinium-based contrast agents (GBCAs) in magnetic resonance imaging (MRI). However, their excellent performance has led to increased use and dosing for many neuro and cardiovascular applications in adults and children.

As a result, concern has been growing in the radiology community, particularly with respect to use of the less stable agents, which are generally linear and, therefore, bind less tightly to the gadolinium (Gd) ion. While recognizing the value of these agents, the US Food and Drug Administration (FDA) and the American College of Radiology (ACR) now recommend limiting patient Gd exposure where possible. One technique for reducing Gd exposure is to use a high-relaxivity

One technique for reducing Gd exposure is to use a high-relaxivity GBCA that can be used at a lower dose than a conventional GBCA without impact on image quality. Until recently, however, the GBCA with the highest relaxivity was a linear agent. Consequently, it has been widely recognized for some time that it would be preferable if a GBCA was both macrocyclic in structure and high relaxivity, and that such an agent could be used to reduce Gd exposure by decreasing the amount of Gd injected.

A new GBCA that is both macrocyclic and high relaxivity has been developed and received FDA marketing approval in September 2022. A group of radiologists with extensive experience in contrast-enhanced (CE)-MRI convened to discuss this new GBCA, Elucirem™ (gadopiclenol) injection, and this monograph presents a summary of this expert panel forum.